Xyphos is committed to the mission of developing a flexible and controllable CAR-T cell therapy to provide patients with the possibility of a durable cure from cancer. Our convertibleCAR™ technology enables the precise control of a CAR-T cell using any tumor-specific antibody, thereby providing a therapeutic platform that;
- improves CAR-T safety and accesses new target space,
- prevents tumor recurrence by enabling target switching or multiplexing, and
- broadens potential indications through deployment of a convertibleCAR-T therapeutic.
Backed by strong issued and pending patents, Xyphos is merging cellular and antibody therapeutics to achieve safety, efficacy and versatility – ultimately bringing promising therapies to cancer patients.